New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

CRISPR Therapeutics AG

Contributing Author

Recent Articles by CRISPR Therapeutics AG

9 hours	CRISPR Therapeutics Presents New Preclinical Data for CTX460 Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Editing Platform CRSP GlobeNewswire
Oct-01	CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress CRSP GlobeNewswire
Sep-22	CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe CRSP GlobeNewswire
Sep-09	CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025 CRSP GlobeNewswire
Sep-02	CRISPR Therapeutics to Participate in Upcoming Investor Conferences CRSP GlobeNewswire
Aug-04	CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results CRSP GlobeNewswire
Jun-30	CRISPR Therapeutics Named to TIME's Most Influential Companies List of 2025 CRSP GlobeNewswire
Jun-26	CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline CRSP GlobeNewswire
May-29	CRISPR Therapeutics to Participate in Upcoming Investor Conferences CRSP GlobeNewswire
May-19	CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies CRSP GlobeNewswire
May-06	CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310 Targeting ANGPTL3 CRSP GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.